Evidence grade: WEAK — Supported only by weak or preliminary evidence.
computed from the encoded evidence by the Atlas grading rule.
Advanced imaging (DSC rCBV, DCE, diffusion, amino-acid PET) separates the two on average in cohorts
At the single-patient level thresholds are non-transferable across scanners/protocols; confirmation-scan waiting remains the de-facto standard
Premature therapy discontinuation vs. continuing ineffective toxic therapy; a core daily neuro-oncology decision
This is an educational research resource from Resonant Labs, not clinical advice. Evidence grades and controversies are summarized from the literature and may change as the field evolves.